Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
NCT ID: NCT00660803
Last Updated: 2010-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2008-05-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
NCT02383030
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
NCT03447132
Observational Study on the Treatment of Patients With Metastatic Breast Cancer
NCT06676436
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
NCT02530411
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
NCT02690480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
Fulvestrant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fulvestrant
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopausal status at the time of treatment with fulvestrant
* Failure of at least one previous endocrine therapy before treatment with fulvestrant.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dendrix - Scientific Information Architecture
UNKNOWN
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Recife, Pernambuco, Brazil
Research Site
Rio de Janeiro, Rio de Janeiro, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OBR-FAS-2007/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.